Bortezomib retreatment is effective in relapsed multiple
myeloma patients - real-life clinical practice data

J 2020

Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Lucie BROŽOVÁ, I. SPICKA, V. MAISNAR et. al.

Basic information

Original name

Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data

Authors

ŠTORK, Martin (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), I. SPICKA (203 Czech Republic), V. MAISNAR (203 Czech Republic), J. MINARIK (203 Czech Republic), A. JUNGOVA (203 Czech Republic), E. GREGORA (203 Czech Republic), Roberta VELICHOVÁ (703 Slovakia, belonging to the institution), R. HAJEK (203 Czech Republic), T. JELINEK (203 Czech Republic) and Luděk POUR (203 Czech Republic, guarantor)

Edition

Neoplasma, Bratislava, Slovenská akademie vied, 2020, 0028-2685

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Slovakia

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.575

RIV identification code

RIV/00216224:14110/20:00115970

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.4149/neo_2019_190430N383

UT WoS

000542659200021

Keywords in English

multiple myeloma; bortezomib; proteasome inhibitor; repeated treatment; relapse

Abstract

V originále

Nowadays, bortezomib, a proteasome inhibitor, is widely used in treatment of newly diagnosed or relapsed multiple myeloma. 'I he aim of this study was to analyze efficiency of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. From 2004 to 2016, 283 patients were retrospectively evaluated at all hematological centers in the Czech Republic. Bortezomib was administered at the standard dosing and in combined therapy with corticosteroids, chemotherapy or thalidomide. Before bortezomib retreatment, 61% of patients received previous lenalidomide treatment, 40.6% autologous transplantation, and median number of prior lines of therapy was three. In total, 21% of patients were refractory to the first bortezomib treatment. In bortezomib retreatment, overall response rate was 34.5%, median progression-free survival was 7.8 months (95% CI: 6.7-8.9), median duration of response was 10.5 months (95% CI: 8.0-13.0) and median overall survival was 20.3 months (95% CI: 17.9-22.7). Grade 3-4 adverse events included thrombocytopenia, neutropenia, anemia and infection. Neuropathy grade 2 or higher occurred in 19.4% of patients. We conclude that bortezomib retreatment is an effective and safe therapeutic alternative for relapsed or refractory multiple myeloma patients.

Citovat

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Lucie BROŽOVÁ, I. SPICKA, V. MAISNAR, J. MINARIK, A. JUNGOVA, E. GREGORA, Roberta VELICHOVÁ, R. HAJEK, T. JELINEK and Luděk POUR. Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data. Neoplasma. Bratislava: Slovenská akademie vied, 2020, vol. 67, No 1, p. 178-184. ISSN 0028-2685. Available from: https://dx.doi.org/10.4149/neo_2019_190430N383.

@article{1670231,
   author = {Štork, Martin and Ševčíková, Sabina and Brožová, Lucie and Spicka, I. and Maisnar, V. and Minarik, J. and Jungova, A. and Gregora, E. and Velichová, Roberta and Hajek, R. and Jelinek, T. and Pour, Luděk},
   article_location = {Bratislava},
   article_number = {1},
   doi = {http://dx.doi.org/10.4149/neo_2019_190430N383},
   keywords = {multiple myeloma; bortezomib; proteasome inhibitor; repeated treatment; relapse},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data},
   url = {http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6465&category_id=160&option=com_virtuemart&vmcchk=1&Itemid=1},
   volume = {67},
   year = {2020}
}

TY  - JOUR
ID  - 1670231
AU  - Štork, Martin - Ševčíková, Sabina - Brožová, Lucie - Spicka, I. - Maisnar, V. - Minarik, J. - Jungova, A. - Gregora, E. - Velichová, Roberta - Hajek, R. - Jelinek, T. - Pour, Luděk
PY  - 2020
TI  - Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data
JF  - Neoplasma
VL  - 67
IS  - 1
SP  - 178-184
EP  - 178-184
PB  - Slovenská akademie vied
SN  - 00282685
KW  - multiple myeloma
KW  - bortezomib
KW  - proteasome inhibitor
KW  - repeated treatment
KW  - relapse
UR  - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6465&category_id=160&option=com_virtuemart&vmcchk=1&Itemid=1
L2  - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6465&category_id=160&option=com_virtuemart&vmcchk=1&Itemid=1
N2  - Nowadays, bortezomib, a proteasome inhibitor, is widely used in treatment of newly diagnosed or relapsed multiple myeloma. 'I he aim of this study was to analyze efficiency of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. From 2004 to 2016, 283 patients were retrospectively evaluated at all hematological centers in the Czech Republic. Bortezomib was administered at the standard dosing and in combined therapy with corticosteroids, chemotherapy or thalidomide. Before bortezomib retreatment, 61% of patients received previous lenalidomide treatment, 40.6% autologous transplantation, and median number of prior lines of therapy was three. In total, 21% of patients were refractory to the first bortezomib treatment. In bortezomib retreatment, overall response rate was 34.5%, median progression-free survival was 7.8 months (95% CI: 6.7-8.9), median duration of response was 10.5 months (95% CI: 8.0-13.0) and median overall survival was 20.3 months (95% CI: 17.9-22.7). Grade 3-4 adverse events included thrombocytopenia, neutropenia, anemia and infection. Neuropathy grade 2 or higher occurred in 19.4% of patients. We conclude that bortezomib retreatment is an effective and safe therapeutic alternative for relapsed or refractory multiple myeloma patients.
ER  -

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Lucie BROŽOVÁ, I. SPICKA, V. MAISNAR, J. MINARIK, A. JUNGOVA, E. GREGORA, Roberta VELICHOVÁ, R. HAJEK, T. JELINEK and Luděk POUR. Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data. \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2020, vol.~67, No~1, p.~178-184. ISSN~0028-2685. Available from: https://dx.doi.org/10.4149/neo\_{}2019\_{}190430N383.

Detailed Information on Publication Record